» Articles » PMID: 36831679

Safety of Cryopreserved Stem Cell Infusion Through a Peripherally Inserted Central Venous Catheter

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Feb 25
PMID 36831679
Authors
Affiliations
Soon will be listed here.
Abstract

The management of patients undergoing stem cell transplantation requires a multipurpose central venous catheter (CVC) to facilitate drug administration, parenteral nutrition, transfusion of blood products, and collection of blood samples. Peripherally inserted central venous catheters (PICCs) appear to meet these requirements but are rarely used for stem cell infusion. We aimed to retrospectively assess the safety and feasibility of stem cell infusion through PICC and to evaluate its impact on transplantation kinetics. We retrospectively analyzed the outcomes of peripheral blood stem cell (PBSC) transplantation in patients receiving cryopreserved autologous or allogeneic PBSC by PICCs and compared the results with patients receiving transplants through a conventionally inserted central venous catheter (CICC). Despite statistically significant differences in CD34 dose, infusion rate, and total length of administration, the clinical outcomes of transplantation, exemplified by platelet and neutrophil engraftment, along with the length of hospitalization, were not affected by the prolonged infusion time and lower infusion velocity in the PICC group. Our study showed that the clinical outcomes of PBSC transplantation did not differ between the PICC and CICC groups, suggesting that both types of catheters can be implemented in a PBSC transplantation setting.

Citing Articles

Incidence of Catheter-Associated Bloodstream Infections in Stem Cell Recipients-Should We Be "PICCy"?.

Milczarek S, Kulig P, Piotrowska O, Zuchmanska A, Wilk-Milczarek E, Machalinski B Cancers (Basel). 2024; 16(6).

PMID: 38539571 PMC: 10969275. DOI: 10.3390/cancers16061239.

References
1.
Kilari D, DSouza A, Fraser R, Qayed M, Davila O, Agrawal V . Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019; 25(6):1099-1106. PMC: 6559839. DOI: 10.1016/j.bbmt.2019.02.015. View

2.
Snowden J, Sanchez-Ortega I, Corbacioglu S, Basak G, Chabannon C, de la Camara R . Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022; 57(8):1217-1239. PMC: 9119216. DOI: 10.1038/s41409-022-01691-w. View

3.
Chopra V, Anand S, Hickner A, Buist M, Rogers M, Saint S . Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet. 2013; 382(9889):311-25. DOI: 10.1016/S0140-6736(13)60592-9. View

4.
Park E, Park K, Kim J, Oh S, Jung K, Oh S . Safety, Efficacy, and Patient Satisfaction with Initial Peripherally Inserted Central Catheters Compared with Usual Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study. Cancer Res Treat. 2020; 53(3):881-888. PMC: 8291194. DOI: 10.4143/crt.2020.1008. View

5.
Sakai T, Kohda K, Konuma Y, Hiraoka Y, Ichikawa Y, Ono K . A role for peripherally inserted central venous catheters in the prevention of catheter-related blood stream infections in patients with hematological malignancies. Int J Hematol. 2014; 100(6):592-8. DOI: 10.1007/s12185-014-1677-9. View